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Abstract
The development of responsive nanomaterials—nanoscale systems that actively respond to stimuli
—is one general goal of nanotechnology. Here we develop nanoparticles that can be controllably
triggered to synthesize proteins. The nanoparticles consist of lipid vesicles filled with the cellular
machinery responsible for transcription and translation, including amino acids, ribosomes, and
DNA caged with a photo-labile protecting group. These particles served as nanofactories capable
of producing proteins including green fluorescent protein (GFP) and enzymatically-active
luciferase. In vitro and in vivo, protein synthesis was spatially and temporally controllable, and
could be initiated by irradiating micron-scale regions on the timescale of milliseconds. The ability
to control protein synthesis inside nanomaterials may enable new strategies to facilitate the study
of orthogonal proteins in a confined environment and for remotely-activated drug delivery.
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Reconstituting protein synthesis at the nanoscale requires the integration of a large number
of cellular components.1–3 Though DNA encodes the complete information required to
specify the amino acid sequence of a protein, several cellular machines are required to
decode this information in order to generate functional proteins.4, 5 Here, we encapsulated
the machinery required to achieve transcription and translation inside of artificial
membranes, producing micro- and nano-particles capable of synthesizing functional
proteins. These systems were subsequently engineered to induce expression in response to
an external stimulus, allowing temporal and spatial control of protein production in vitro and
in vivo.
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To create particles capable of synthesizing proteins, phospholipid vesicles were formed
around a minimal E. coli S30 extract and plasmid DNA template encoding a reporter protein
(Fig.1a). The cell extract was used as the source of biochemical machinery, energy, ions,
and T7 RNA polymerase.6 cDNA was used to eliminate complexities associated with
mRNA splicing.7 To form vesicles, a phospholipid that self-assembles into soft lipid
bilayers at physiological temperature was used (1,2-dimyristoyl-sn-glycero-3-
phosphocholine (DMPC); a phosphatidylcholine with two 14-carbon tails). Micro-scale
vesicles were formed spontaneously after mixing the extract and DNA with DMPC. The
particles were collected by centrifugation, and non-entrapped extract, DNA, and protein
were removed by repeated washing.
The lipid vesicles were capable of producing GFP, imaged using fluorescence microscopy
(Fig. 1b). GFP only fluoresces if folded properly,8 confirming that the fluorescent particles
contained all components necessary for transcription, translation, and folding. The particles
assumed a vesicular structure, with GFP encapsulated in the aqueous core. Confocal
microscopy showed that the protein was dispersed throughout the inner core of the vesicles
and not bound to the outside of the membrane (Fig. 1c).
To test if the particles were capable of producing proteins that are enzymatically active, a
template encoding Renilla luciferase was incorporated into the particles. After the particles
were collected and thoroughly washed, they were lysed, and the internal contents were
examined by the complementary assays of immunoblotting (Supplementary Fig. S1) and
bioluminescence (Fig. 2a). When luciferin was added to the lysate, the solution emitted
robust luminescence (1.01 × 107 AU), indicating that the luciferase produced in the particles
was enzymatically active.9
To test if protein-producing particles have a minimum size constraint, nanoparticles of
various sizes were formed by extrusion. Particles with average diameters of ~400, 250, and
170 nm were all capable of producing functional luciferase; however, 100 nm particles were
not (Fig. 2a). CryoTEM images (Fig. 2b) suggest that the 170 nm extruded nanoparticles
display an elliptical morphology with the ribosomes and code inside. Testing the internal
content of the 100 nm particles showed they lack DNA (Fig. 2e), thus explaining why they
are dysfunctional. In these studies we used a luciferase-encoding 4 kb (~1360 nm long)
plasmid, Fig. 2f. For such a plasmid to fit into a nanoparticle it must supercoil (Fig. 2g). One
possibility is that the spontaneous supercoiling to fit the dimensions of the smallest particle
(<100 nm) is inefficient10, 11 and may require additional condensing agents, such as cationic
lipids.
Interestingly, when comparing the total amount of protein produced, dispersions with
smaller particles (170 or 250 nm) produced more protein than dispersions with larger (400
nm) particles, Fig. 2. Comparing the internal content of the different particles showed that
while 170 nm particles produced 81±9 proteins/particle, the 400 nm particles, which have a
13-times greater volume, produced only 190±15 proteins/particle. This observation that
smaller particles are more efficient in producing proteins has also been suggested in other
studies that tested protein production at the nanoscale.12–15 While the exact reason for this
phenomenon is unclear, it seems possible that the close proximity of the ‘reacting’
components (e.g., nucleoside 5´-triphosphates (NTPs) and amino acids) to the machinery
(e.g., RNA polymerase and ribosomes) plays a role in more efficient use of resources during
these processes.
We next sought to develop nanoparticles wherein protein production can be remotely
triggered in vitro and in vivo. To control the production of proteins temporally, a photo-
labile protecting group was conjugated to the DNA.16 Luciferase-encoding DNA was caged
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with 1-(4,5-dimethoxy-2-nitrophenyl) diazoethane (DMNPE) to block transcription. UV
irradiation at 365 nm uncaged the DNA, and luciferase was produced.
To better understand the timescale of irradiation necessary to activate the particles and to
test if they could be activated when flowing at the speed of physiological blood flow,17
particles were irradiated while flowing through a 100 µm-wide microfluidic channel (Fig.
3a) using 300–400 nm light at 120 mW/cm2. Although these wavelengths have tissue
penetration of ~10 mm,18 two photon microscopy could be used to deepen penetration
significantly in the future.19, 20 Flow velocity was varied, and the rate of luciferase
production decreased as velocity increased (Fig. 3b). This was expected, as the amount of
time that the particles were in the patch of light decreased as flow velocity increased. When
light was irradiated through a microscope objective, the particles were activated in as short
as 10 ms at physiological flow velocity (2 cm/s). Notably, luciferase production in the
flowing channel could be activated in a pulsatile manner by modulating the light source
(Fig. 3c).
To examine whether the particles could be remotely activated to produce luciferase in vivo,
particles were injected locally into mice. The animals were either irradiated at the site of the
injection or left untreated. Whole body bioluminescence imaging confirmed robust
production of luciferase expression, which persisted for at least 24 hours (Fig. 3d,e). While
the quantum efficiency in vitro is in the range of 10–40 photons per protein produced (Fig.
3b), in vivo this ratio grows to approx. 6500 photons per protein. This is explained by the
attenuation of UV rays in tissue.21, 22
Such an approach, in which autonomous nanoscale production units are located in the body
and can be remotely activated to synthesize a potent compound from inert precursors, may
find utility in the localized delivery of therapeutics.23–27 To date, this objective has been met
for therapeutic applications only with live bacteria that were predesigned to produce proteins
in disease sites.28–30 Unlike bacterial systems, artificial systems are modular, and their
physical/chemical properties can be modified. Incorporating mechano-synthesis functions in
nanomaterials may have applications in both basic biophysics and in medicine.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We thank Phillip Sharp for his support. AS was supported by the Misrock Foundation. CK was a Johnson &
Johnson fellow of the Life Sciences Research Foundation. This work was supported by MIT-Harvard Center for
Cancer Nanotechnology Excellence Grant U54 CA151884 from the National Cancer Institute, by a generous gift
from the Marie D. & Pierre Casimir-Lambert Fund to Phillip Sharp and partially by the Cancer Center Support
(core) grant P30-CA14051 from the National Cancer Institute. This work was supported by NIH grant # EB000244
to RL and DGA. The cryoTEM imaging was performed by NanoImaging Services, Inc. (La Jolla, CA). Donald
Gantz, Boston University, also helped with cryoTEM imaging (Fig. 2b).
REFERENCES
1. Jain RK, Stylianopoulos T. Nat Rev Clin Oncol. 2010; 7(11):653–664. [PubMed: 20838415]
2. Szostak JW, Bartel DP, Luisi PL. Nature. 2001; 409(6818):387–390. [PubMed: 11201752]
3. Hulme SE, Whitesides GM. Angew Chem Int Ed Engl. 2011; 50(21):4774–4807. [PubMed:
21500322]
4. Bustamante C, Cheng W, Mejia YX. Cell. 2011; 144(4):480–497. [PubMed: 21335233]
5. Shimizu Y, Inoue A, Tomari Y, Suzuki T, Yokogawa T, Nishikawa K, Ueda T. Nat Biotechnol.
2001; 19(8):751–755. [PubMed: 11479568]
Schroeder et al. Page 3
Nano Lett. Author manuscript; available in PMC 2013 June 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
6. Nevin DE, Pratt JM. FEBS Lett. 1991; 291(2):259–263. [PubMed: 1936272]
7. Early P, Rogers J, Davis M, Calame K, Bond M, Wall R, Hood L. Cell. 1980; 20(2):313–319.
[PubMed: 6771020]
8. Cody CW, Prasher DC, Westler WM, Prendergast FG, Ward WW. Biochemistry. 1993; 32(5):1212–
1218. [PubMed: 8448132]
9. Paulmurugan R, Gambhir SS. Anal Chem. 2003; 75(7):1584–1589. [PubMed: 12705589]
10. Vologodskii A, Cozzarelli NR. Biophys J. 1996; 70(6):2548–2556. [PubMed: 8744294]
11. Burnier Y, Dorier J, Stasiak A. Nucleic Acids Res. 2008; 36(15):4956–4963. [PubMed: 18658246]
12. Siuti P, Retterer ST, Choi CK, Fowlkes JD, Doktycz MJ. Annual ORNL Biomedical Science and
Engineering Center Conference ORNL Biomedical Science and Engineering Center Conference.
2009; 2009:1–4. [PubMed: 21278819]
13. Siuti P, Retterer ST, Doktycz MJ. Lab Chip. 2011; 11(20):3523–3529. [PubMed: 21879140]
14. Angenendt P, Nyarsik L, Szaflarski W, Glokler J, Nierhaus KH, Lehrach H, Cahill DJ, Lueking A.
Anal Chem. 2004; 76(7):1844–1849. [PubMed: 15053642]
15. Mei Q, Fredrickson CK, Simon A, Khnouf R, Fan ZH. Biotechnol Prog. 2007; 23(6):1305–1311.
[PubMed: 17924644]
16. Monroe WT, McQuain MM, Chang MS, Alexander JS, Haselton FR. J Biol Chem. 1999; 274(30):
20895–20900. [PubMed: 10409633]
17. Drew PJ, Shih AY, Driscoll JD, Knutsen PM, Blinder P, Davalos D, Akassoglou K, Tsai PS,
Kleinfeld D. Nat Methods. 2010; 7(12):981–984. [PubMed: 20966916]
18. Ran C, Zhang Z, Hooker J, Moore A. Mol Imaging Biol. 2011
19. Collins HA, Khurana M, Moriyama EH, Mariampillai A, Dahlstedt E, Balaz M, Kuimova MK,
Drobizhev M, Yang V, Phillips D, Rebane A, Wilson BC, Anderson HL. Nature Photonics. 2008;
2:420–424.
20. Gagey N, Neveu P, Jullien L. Angew Chem Int Ed Engl. 2007; 46(14):2467–2469. [PubMed:
17310488]
21. Meinhardt M, Krebs R, Anders A, Heinrich U, Tronnier H. J Biomed Opt. 2008; 13(4) 044030.
22. Crippa R, Cristofoletti V, Romeo N. Biochim. Biophys. Acta. 1978; 538:164–170. [PubMed:
563737]
23. Schrum JP, Zhu TF, Szostak JW. Cold Spring Harb Perspect Biol. 2010; 2(9) a002212.
24. Ma C, Fan R, Ahmad H, Shi Q, Comin-Anduix B, Chodon T, Koya RC, Liu CC, Kwong GA,
Radu CG, Ribas A, Heath JR. Nat Med. 2011; 17(6):738–743. [PubMed: 21602800]
25. Liang G, Ren H, Rao J. Nat Chem. 2010; 2(1):54–60. [PubMed: 21124381]
26. Ashley CE, Carnes EC, Phillips GK, Padilla D, Durfee PN, Brown PA, Hanna TN, Liu J, Phillips
B, Carter MB, Carroll NJ, Jiang X, Dunphy DR, Willman CL, Petsev DN, Evans DG, Parikh AN,
Chackerian B, Wharton W, Peabody DS, Brinker CJ. Nat Mater. 2011; 10(5):389–397. [PubMed:
21499315]
27. Noireaux V, Libchaber A. Proc Natl Acad Sci U S A. 2004; 101(51):17669–17674. [PubMed:
15591347]
28. Forbes NS. Nat Rev Cancer. 2010; 10(11):785–794. [PubMed: 20944664]
29. Min JJ, Nguyen VH, Kim HJ, Hong Y, Choy HE. Nat Protoc. 2008; 3(4):629–636. [PubMed:
18388945]
30. Loeffler M, Le'Negrate G, Krajewska M, Reed JC. Proc Natl Acad Sci U S A. 2007; 104(31):
12879–12883. [PubMed: 17652173]
Schroeder et al. Page 4
Nano Lett. Author manuscript; available in PMC 2013 June 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Schroeder et al. Page 5
Nano Lett. Author manuscript; available in PMC 2013 June 13.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FIGURE 1. Protein producing particles
(a) A schematic of an encapsulated in vitro transcription/translation nano- and micro-scale
particulate system. DNA, tRNA, ribosomes, amino acids, ribonucleotide tri-phosphates
(rNTPs) and ions were loaded into lipid vesicles. Protein production can be triggered by
irradiating caged DNA with light. (b) Overlaid transmitted light and fluorescence images of
a GFP-producing particle. (c) Confocal images of four sections from a single particle. GFP
is seen throughout the inside of the vesicle. Bar 5 µm.
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FIGURE 2. Particles are functional at the nano-scale but have a minimum size constraint
(a) Total luciferase activity is shown for particles extruded to various sizes. No signal is
observed for particles with a diameter of 100 nm. (b) A cryoTEM micrograph of 170 nm
particles, with structures resembling ribosomes (c), and DNA (d) inside them. (d) The cross-
section between the two green arrows is ~2.3 nm, that of DNA. While DNA is detected in
particles 170 nm or larger (e) it remains at baseline levels in the 100 nm particles; explaining
why the smaller particles are dysfunctional. AFM images (f) of the 4kb, luciferase-encoding,
plasmid in solution reveal its unfolded dimensions (~1360 nm long) and that the plasmid
must supercoil (g) in order to fit into the nanoparticles. To fit into a 100-nm particle the
supercoiled plasmid would need at least 4 writhes in its configuration, while only 2 writhes
are needed to fit into a 170-nm particle.
Graph bars are the mean±S.D. of 3 separate experiments with 4 experimental points each.
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FIGURE 3. Protein production can be remotely triggered
(a) A schematic of the inducible system in microfluidic channels. The formulated DNA is
caged by DMNPE, which is released by irradiation with UV light, permitting transcription to
occur. Following UV exposure, the particles were incubated for 1 hr at 37 °C to ensure
completion of the protein production process. (b) Protein production in 200 nm
nanoparticles is inversely correlated with flow velocity in a microfluidic channel (black
bars). The quantum efficiency, i.e., the number proteins produced per absorbed photons, is
proportional to flow velocity (b, grey bars) (c) The rate of luciferase production in a solution
of 200 nm nanoparticles flowing through a microfluidic channel at a flow velocity of 2 cm/s,
with and without irradiation. (d–e) Uncaging of DNA by local UV irradiation induces the
production of luciferase in vivo. (d) Representative whole body bioluminescence imaging of
mice injected locally with particles containing caged luciferase-encoding DNA. After
injection the mice were either administered UV (400 mW/cm2) at the site of injection or left
untreated. (e), Quantitation of the whole body bioluminescence imaging shown in (d).
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